

Invitation to SynAct Pharma's Capital Markets Day in Stockholm June 4

SynAct Pharma AB ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system, invites investors, analysts and media to a Capital Markets Day on Wednesday, June 4, 15:00-17:00 CEST in Stockholm.

SynAct is progressing with the recruitment of patients to its Phase 2b ADVANCE study in patients with newly diagnosed severe rheumatoid arthritis (RA) and is accelerating its plans to expand the use of resomelagon into other indications. Please join the CMD to hear about SynAct's efforts and path forward.

Agenda

15.00 **Introduction by Chairman** – Anders Kronborg

15.10 **Corporate Update** – Jeppe Øvlesen, CEO

15:25 **Resomelagon**

- *Induce inflammatory resolution through biased agonism at the melanocortin system*
- *Parallel development tracks*

15:45 **Inflammatory and Autoimmune diseases**

- *Positioning and development in Rheumatoid Arthritis*
- *The Advance study*
- *New opportunities in Rheumatic diseases*

16:15 **Host-directed therapy in Viral infections** – Professor Mauro Teixeira

- *Preclinical update*
- *The RESOVIR-2 study in Dengue*

16:45 **The TXP program**

16:55 **Wrap-up and summary** – Jeppe Øvlesen, CEO

17:00 **Mingle and drinks**

When: June 4, 2025, from 15:00-17:00 CEST

Location: Investor Studios, Hötorgsskrapan 3

Address: Sveavägen 9 or Mäster Samuelsgatan 42 or Sergelgatan 8 – 10, Floor 7

Additional information:

If you enter the building via Sveavägen 9 or Sergelgatan 8 – 10, choose the escalator, turn to the left after entering the next floor and choose the elevator in front of you (floor 7)

If you enter the building via Mäster Samuelsgatan 42, go straight ahead and pass the reception and continue towards the elevators you see in front of you (floor 7).

Follow the broadcast live here:

<https://www.youtube.com/live/COqFXRFQP0Q?si=eFOOty9RtXaBSMri>

The Capital Markets Day will be held in English. Presentation material will be available on SynAct's website afterwards.

Registration for the event is made by mailing investor.relations@synactpharma.com

For further information, please contact:

Jeppe Øvlesen

CEO, SynAct Pharma AB

Phone: + 45 2844 7567

E-mail: investor.relations@synactpharma.com

Attachments

[Invitation to SynAct Pharma's Capital Markets Day in Stockholm June 4](#)